Post-Marketing Surveillance of Lenvima in Korean Patients

NCT02764554 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2021-10-07

No results posted yet for this study

Summary

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Conditions

  • Differentiated Thyroid Carcinoma (DTC)

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-10
Primary Completion
2021-09-29
Completion
2021-09-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02764554 on ClinicalTrials.gov